The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 2 May 2026•Updated 2 May 2026•

1 min read

Sanctuary Advisors Boosts Incyte Stake by 87.7% Following Robust Earnings

Key Facts

1Sanctuary Advisors LLC increased its stake in Incyte Corporation by 87.7%, bringing its total holdings to $3.16 million.

2Incyte reported an EPS of $1.81 and revenue of $1.27 billion, marking a 20.9% year-over-year increase.

Sanctuary Advisors LLC increased its stake in Incyte Corporation by 87.7% to $3.16 million following a strong financial performance where revenue hit $1.27 billion. Recent analyst updates have added further context, with H.C. Wainwright reiterating a 'Buy' rating based on the clinical flexibility and deepening effectiveness of povorcitinib in treating hidradenitis suppurativa. Meanwhile, Citizens JMP affirmed a 'Market Perform' rating, suggesting that Incyte's current portfolio implementation is well-positioned to offset the upcoming ruxolitinib patent cliff. These clinical advancements follow a robust quarterly report featuring an EPS of $1.81, which exceeded market expectations. The combination of institutional accumulation and positive trial data highlights a strategic pivot toward new therapeutic drivers. Investors remain focused on the company's ability to transition its revenue base ahead of key patent expirations.

about 1 month ago

Version History

1 additional source confirmed this story

Version 1about 1 month ago

What changed: The story was updated to include reaffirmed analyst ratings from H.C. Wainwright and Citizens JMP, along with new clinical trial data for povorcitinib.